Assessing the impact of COVID-19 on liver cancer management (CERO-19).
Assessing the impact of COVID-19 on liver cancer management (CERO-19).
复制标题
DOI：
10.1016/j.jhepr.2021.100260
复制
发表时间：
2021-06
期刊：
影响因子：
--
通讯作者：
Reig M
中科院分区：
文献类型：
--
作者：
Muñoz-Martínez S;Sapena V;Forner A;Nault JC;Sapisochin G;Rimassa L;Sangro B;Bruix J;Sanduzzi-Zamparelli M;Hołówko W;El Kassas M;Mocan T;Bouattour M;Merle P;Hoogwater FJH;Alqahtani SA;Reeves HL;Pinato DJ;Giorgakis E;Meyer T;Villadsen GE;Wege H;Salati M;Mínguez B;Di Costanzo GG;Roderburg C;Tacke F;Varela M;Galle PR;Alvares-da-Silva MR;Trojan J;Bridgewater J;Cabibbo G;Toso C;Lachenmayer A;Casadei-Gardini A;Toyoda H;Lüdde T;Villani R;Matilla Peña AM;Guedes Leal CR;Ronzoni M;Delgado M;Perelló C;Pascual S;Lledó JL;Argemi J;Basu B;da Fonseca L;Acevedo J;Siebenhüner AR;Braconi C;Meyers BM;Granito A;Sala M;Rodríguez-Lope C;Blaise L;Romero-Gómez M;Piñero F;Gomez D;Mello V;Pinheiro Alves RC;França A;Branco F;Brandi G;Pereira G;Coll S;Guarino M;Benítez C;Anders MM;Bandi JC;Vergara M;Calvo M;Peck-Radosavljevic M;García-Juárez I;Cardinale V;Lozano M;Gambato M;Okolicsanyi S;Morales-Arraez D;Elvevi A;Muñoz AE;Lué A;Iavarone M;Reig M
2019冠状病毒病（COVID-19）大流行对医疗保健系统构成了前所未有的挑战，并可能严重影响肝癌（LC）患者。在此，我们评估了LC筛查或程序的时间表是否因COVID-19大流行而中断或延迟。一项国际调查评估了2020年3月至2020年6月期间COVID-19大流行对临床实践和临床试验的影响，作为多中心、国际和观察性项目的第一阶段。重点是在第一波COVID-19大流行期间在世界各地接受治疗的肝细胞癌或肝内胆管癌患者。91家中心表示有兴趣参与，76家中心被纳入分析，分别来自欧洲、南美洲、北美洲、亚洲和非洲（各大洲分别为73.7%、17.1%、5.3%、2.6%和1.3%）。87%的中心修改了其临床实践：40.8%的诊断程序，80.9%的筛查计划，50%取消了LC的治愈性和/或姑息性治疗，41.7%修改了肝移植计划。在69个正在进行临床试验的中心中，有45个（65.2%）在这种情况下修改了治疗方法，但58.1%的中心能够招募新患者。在COVID-19大流行之前提供电话呼叫服务的中心中，有51. 4%的中心修改了该服务（n = 19/37）。2019冠状病毒病第一波大流行对肝癌患者的常规护理产生了巨大影响。筛查、诊断和治疗算法的修改可能会显著损害患者的结局。正在进行的数据收集和今后的分析将报告所实施战略的利弊，以协助今后的决策。2019冠状病毒病（COVID-19）大流行对全球医疗系统构成前所未有的挑战。在此，我们评估了第一波大流行对肝癌患者的影响，发现这些患者的常规护理已被严重破坏，这可能对结果产生重大影响。2019冠状病毒病（COVID-19）大流行对肝癌管理产生全球影响。80.9%的参与中心修改或取消了筛查计划。几乎所有中心都取消或推迟了除全身治疗外的所有治疗。电话访问是第一波患者随访的工具。护士的作用是维持临床实践和临床试验的关键。
The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic. An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave. Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37). The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making. The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes. The coronavirus disease 2019 (COVID-19) pandemic had a worldwide impact on liver cancer management. Screening programmes were modified or cancelled in 80.9% of participating centres. All but systemic treatments were cancelled or delayed in almost all centres. Phone call visits were the tools for patient follow-up during the first wave. The role of the nurses was key to maintaining clinical practice and clinical trials.
登录
查看更多内容
影响因子：
13.5
作者：
Rich, Nicole E.;John, Binu V.;Singal, Amit G.
通讯作者：
Singal, Amit G.
影响因子：
25.7
作者：
Cucchetti, Alessandro;Trevisani, Franco;Pinna, Antonio D.
通讯作者：
Pinna, Antonio D.
影响因子：
4
作者：
Waterhouse, David M.;Harvey, R. Donald;Schilsky, Richard L.
通讯作者：
Schilsky, Richard L.
影响因子：
4.2
作者：
Kudo, Masatoshi;Kurosaki, Masayuki;Sakamoto, Naoya
通讯作者：
Sakamoto, Naoya
DOI：
10.1016/j.jhepr.2020.100199
发表时间：
2021-03
期刊：
JHEP reports : innovation in hepatology
影响因子：
--
作者：
Amaddeo G;Brustia R;Allaire M;Lequoy M;Hollande C;Regnault H;Blaise L;Ganne-Carrié N;Séror O;Larrey E;Lim C;Scatton O;El Mouhadi S;Ozenne V;Paye F;Balladur P;Dohan A;Massault PP;Pol S;Dioguardi Burgio M;Vilgrain V;Sepulveda A;Cauchy F;Luciani A;Sommacale D;Leroy V;Roudot-Thoraval F;Bouattour M;Nault JC;Paris Liver Cancer Group
通讯作者：
Paris Liver Cancer Group